Charles River Laboratories International, Inc. (CRL) recently announced a contract development and manufacturing organization (CDMO) agreement with the Italy-based clinical-stage biotechnology company, AAVantgarde. The collaboration will produce GMP plasmid DNA to help advance AAVantgarde's platform for treating Stargardt's disease — a condition with significant unmet needs. Significance of the Partnership Charles River will leverage its two-decade-long expertise in manufacturing GMP plasmid DNA to support ...

Charles River Laboratories' (CRL) Research Models and Services (RMS) business continues to benefit from the Charles River Accelerator and Development Labs (CRADL) initiative. Yet, the global business environment remains challenging, denting the company's growth. The stock carries a Zacks Rank #3 (Hold). Within RMS, the company, in November 2023, acquired a 41% additional stake in Noveprim, a NHP provider of Mauritius. This acquisition led to a 90% controlling interest in Noveprim, firmly supporting Charles ...

Charles River's Plasma DNA and Viral Vector CDMO Following the agreement, Gates Institution will have access to Charles River's manufacturing platforms and viral vector CDMO center of excellence, leveraging a range of services, including process development evaluation of Gates Institute's LVV backbone, phase-appropriate research grade, high–quality (HQ) plasmid DNA production and GMP LVV manufacturing. Image Source: Zacks Investment Research Given the market potential, the collaboration between Charles Rive ...

More on the News Industry Prospect In June 2024, Charles River announced a collaboration with MatTek Corporation to develop a New Approach Methodology inhalation toxicology test to reduce reliance on traditional animal research methods. The program will be funded through $1.3 million grant. Charles River currently carries a Zacks Rank #3 (Hold). The Inogen stock has surged 32.4% year to date. In the past 60 days, the bottom-line estimate for 2024 has narrowed from a loss of $2.56 per share to a loss of $2.4 ...

Outlook's 08/30/2023 CRL opened up a world of pain for its shareholders This is my second Outlook Therapeutics (NASDAQ:OTLK) article after 04/2023's "Outlook Therapeutics: August PDUFA For Wet AMD Blockbuster". In that article, I pegged Outlook as a high risk high reward bet on a successful PDUFA. I took the bullish bet, rating Outlook a Buy. In doing so, I noted: There is no wiggle room here. What happens if the FDA extends its PDUFA date by three months as quite common? What happens if the FDA issues a CR ...

The VCG collaboration is a project guided by Charles River's Alternative Methods Advancement Project ("AMAP"), an initiative focused on reducing the use of animals in research. The development is likely to boost the company's Discovery and Safety Assessment ("DSA") segment. As the company enters the next frontier of drug development, AMAP will facilitate strategic and purposeful investing to pave the path where more patients receive needed treatments and medicines safely, swiftly and successfully. Upholding ...

SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders. What can I do? If you are a current Charles River shareholder, you may have legal claims that may be brought on behalf of the company, against CRL's directors and officers. If you wish to ...

Charles River Laboratories International, Inc. (CRL) is well-poised for the coming quarters, on the back of its impressive strategic acquisitions. Stabilization of demand trends within the DSA (Discovery and Safety Assessment) arm is encouraging. The company's sound solvency also instils optimism. However, concerns remain over the adverse impacts of macroeconomic challenges as well as currency fluctuations. In the past year, this Zacks Rank #3 (Hold) company's shares have risen 9.4% compared with 6.1% growt ...

Charles River Laboratories' (CRL) Research Models and Services (RMS) arm continues to gain from the CRADL initiative. Yet, destocking efforts are denting growth in the Manufacturing Solutions business. The stock carries a Zacks Rank #3 (Hold) currently. Within Charles River's RMS segment, the company is witnessing strong growth in the insourcing solutions (IS) business led by the CRADL (Charles River Accelerator and Development Labs) initiative. These days, clients are increasingly adopting CRADL's flexible ...

Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors. Our review of CRL's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts. For the quarter, the company's ...